Drug Panel 9A, Urine - Screen with Reflex to Confirmation/Quantitation
Also known as: CDASU 9A
Use
The Drug Panel 9A, Urine - Screen with Reflex to Confirmation/Quantitation is used for general screening in contexts of compliance and/or abuse. It employs a screen with reflex testing, which is the preferred method for ruling out drug exposure. However, this test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites. The screening serves medical purposes but is not valid for forensic use.
Special Instructions
If a specimen screens positive, then Confirmation/Quantitation by GC/MS, GC/FID, and/or LC-MS/MS will be added to confirm the result. Additional charges apply.
Limitations
Presumptive negative results may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing technology. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. This test cannot distinguish between prescribed or non-prescribed forms of THC, nor between active or passive usage.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 2161-8
- 48767-8
- 19261-7
- 19359-9
- 19300-3
- 19659-2
- 19292-2
- 19270-8
- 14316-4
- 19429-0
- 19550-3
- 46983-3
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
8 mL
Minimum Volume
4 mL
Container
ARUP Standard Transport Tubes
Collection Instructions
Random urine collection. Transfer 8 mL urine with no additives or preservatives.
Storage Instructions
Refrigerated
Causes for Rejection
Specimens exposed to repeated freeze/thaw cycles.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |